US Bancorp’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History

US Bancorp’s Portfolio SGMO Stock Details SGMO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$3	Hold	11	–	–	﹤0.01%	4162
2025 Q4	$5	Hold	11	–	–	﹤0.01%	4030
2025 Q3	$7	Hold	11	–	–	﹤0.01%	3992
2025 Q2	$6	Hold	11	–	–	﹤0.01%	4147
2025 Q1	$7	Sell	11 -12	-52%	-$13	﹤0.01%	4174
2024 Q4	$23	Hold	23	–	–	﹤0.01%	4135
2024 Q3	$20	Sell	23 -512	-96%	-$375	﹤0.01%	4061
2024 Q2	$192	Buy	+535	New	+$289	﹤0.01%	3910
2023 Q4	–	Sell	-5,000	Closed	-$3K	–	4130
2023 Q3	$3K	Hold	5,000	–	–	﹤0.01%	3573
2023 Q2	$6.5K	Sell	5,000 -6,113	-55%	-$8.35K	﹤0.01%	3402
2023 Q1	$19.6K	Buy	11,113 +5,203	+88%	+$14.8K	﹤0.01%	3006
2022 Q4	$18.6K	Sell	5,910 -2,374	-29%	-$9.21K	﹤0.01%	3032
2022 Q3	$41K	Sell	8,284 -185	-2%	-$950	﹤0.01%	2655
2022 Q2	$35K	Buy	8,469 +328	+4%	+$1.42K	﹤0.01%	2781
2022 Q1	$47K	Buy	8,141 +1,482	+22%	+$8.81K	﹤0.01%	2664
2021 Q4	$50K	Buy	6,659 +1,024	+18%	+$8.89K	﹤0.01%	2662
2021 Q3	$51K	Sell	5,635 -55	-1%	-$544	﹤0.01%	2651
2021 Q2	$68K	Buy	5,690 +690	+14%	+$7.81K	﹤0.01%	2506
2021 Q1	$63K	Hold	5,000	–	–	﹤0.01%	2491
2020 Q4	$78K	Hold	5,000	–	–	﹤0.01%	2330
2020 Q3	$47K	Hold	5,000	–	–	﹤0.01%	2431
2020 Q2	$45K	Hold	5,000	–	–	﹤0.01%	2473
2020 Q1	$32K	Sell	5,000 -176	-3%	-$1.31K	﹤0.01%	2553
2019 Q4	$43K	Hold	5,176	–	–	﹤0.01%	2546
2019 Q3	$47K	Hold	5,176	–	–	﹤0.01%	2501
2019 Q2	$56K	Sell	5,176 -134	-3%	-$1.43K	﹤0.01%	2473
2019 Q1	$51K	Hold	5,310	–	–	﹤0.01%	2482
2018 Q4	$61K	Hold	5,310	–	–	﹤0.01%	2357
2018 Q3	$90K	Hold	5,310	–	–	﹤0.01%	2282
2018 Q2	$75K	Sell	5,310 -259	-5%	-$4.3K	﹤0.01%	2373
2018 Q1	$106K	Buy	5,569 +569	+11%	+$12.2K	﹤0.01%	2203
2017 Q4	$82K	Sell	5,000 -750	-13%	-$11.2K	﹤0.01%	2353
2017 Q3	$86K	Buy	5,750 +750	+15%	+$8.29K	﹤0.01%	2317
2017 Q2	$44K	Hold	5,000	–	–	﹤0.01%	2604
2017 Q1	$26K	Hold	5,000	–	–	﹤0.01%	2761
2016 Q4	$15K	Hold	5,000	–	–	﹤0.01%	2928
2016 Q3	$23K	Hold	5,000	–	–	﹤0.01%	2766
2016 Q2	$29K	Hold	5,000	–	–	﹤0.01%	2658
2016 Q1	$30K	Hold	5,000	–	–	﹤0.01%	2614
2015 Q4	$46K	Hold	5,000	–	–	﹤0.01%	2484
2015 Q3	$28K	Hold	5,000	–	–	﹤0.01%	2726
2015 Q2	$55K	Hold	5,000	–	–	﹤0.01%	2478
2015 Q1	$78K	Hold	5,000	–	–	﹤0.01%	2306
2014 Q4	$76K	Hold	5,000	–	–	﹤0.01%	2311
2014 Q3	$54K	Hold	5,000	–	–	﹤0.01%	2455
2014 Q2	$76K	Hold	5,000	–	–	﹤0.01%	2282
2014 Q1	$90K	Hold	5,000	–	–	﹤0.01%	2170
2013 Q4	$69K	Hold	5,000	–	–	﹤0.01%	2284
2013 Q3	$52K	Hold	5,000	–	–	﹤0.01%	2326
2013 Q2	$39K	Buy	+5,000	New	+$43.6K	﹤0.01%	2408

Other funds holding SGMO

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

VFT

Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

US Bancorp's SGMO Position: Q1 2026 in Review

US Bancorp held its SANGAMO THERAPEUTICS INC (SGMO) position steady in Q1 2026 at 11 shares worth $3. The position accounts for ﹤0.01% of the portfolio, ranked #4162.

US Bancorp first reported a position in SGMO in Q2 2013 and has held it in 50 quarters since. The position peaked at $106K in Q1 2018. 112 funds tracked by Wall St. Rank hold SGMO as of Q1 2026.

US Bancorp held 11 shares of SANGAMO THERAPEUTICS INC worth $3 as of Q1 2026.
US Bancorp left its SANGAMO THERAPEUTICS INC share count unchanged in Q1 2026.
SANGAMO THERAPEUTICS INC made up ﹤0.01% of US Bancorp's portfolio in Q1 2026, its #4162 holding.
US Bancorp first reported a position in SANGAMO THERAPEUTICS INC in Q2 2013 and has held it in 50 quarters since.
US Bancorp's SANGAMO THERAPEUTICS INC position peaked at $106K in Q1 2018.
112 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q1 2026.

Based on US Bancorp's 13F filing for Q1 2026, filed 15 May 2026.